利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

21 条记录 (耗时 0.029 秒)

    Direct administration of REIC/Dkk-3 to mesothelioma
    11.
    发明授权
    Direct administration of REIC/Dkk-3 to mesothelioma 有权
    将REIC / Dkk-3直接给予间皮瘤

    公开(公告)号：US09475865B2

    公开(公告)日：2016-10-25

    申请号：US13925041

    申请日：2013-06-24

    申请人： Hiromi Kumon ,  Nam-ho Huh ,  Masakiyo Sakaguchi ,  Yasutomo Nasu ,  Fernando Guillermo Abarzua Cabezas

    发明人： Hiromi Kumon ,  Nam-ho Huh ,  Masakiyo Sakaguchi ,  Yasutomo Nasu ,  Fernando Guillermo Abarzua Cabezas

    IPC分类号： A61K48/00 ,  C12N15/85 ,  C07K16/18 ,  A61K31/711 ,  C07K14/47 ,  A61K38/00

    CPC分类号： C07K16/18 ,  A61K31/711 ,  A61K38/00 ,  A61K48/00 ,  C07K14/4747

    摘要： This invention provides an inducer of apoptosis in cancer cells comprising a fragment of the REIC/Dkk-3 gene and a cancer therapeutic agent comprising the same. This invention also provides a polynucleotide fragment encoding the REIC/Dkk-3 protein (a) or (b), which encodes a polypeptide having apoptosis activity: (a) a polynucleotide encoding a polypeptide comprising an amino acid sequence of amino acid 1 to any of amino acids 39 to 78 of the amino acid sequence of the REIC/Dkk-3 protein as shown in SEQ ID NO: 2; or (b) a polynucleotide encoding a polypeptide comprising an amino acid sequence derived from the amino acid sequence of amino acid 1 to any of amino acids 39 to 78 of the amino acid sequence of the REIC/Dkk-3 protein as shown in SEQ ID NO: 2 by substitution, deletion, or addition of 1 or several amino acids and having apoptosis activity.

    摘要翻译： 本发明提供了包含REIC / Dkk-3基因的片段的癌细胞中的凋亡诱导剂和包含其的癌症治疗剂。 本发明还提供编码具有凋亡活性的多肽的编码REIC / Dkk-3蛋白（a）或（b）的多核苷酸片段：（a）编码包含氨基酸1的氨基酸序列的多肽的多核苷酸至任何 的如SEQ ID NO：2所示的REIC / Dkk-3蛋白的氨基酸序列的氨基酸39至78; 或（b）编码多肽的多核苷酸，其包含衍生自SEQ ID NO：1所示的REIC / Dkk-3蛋白的氨基酸序列的氨基酸1至氨基酸39至78的氨基酸序列的氨基酸序列的氨基酸序列 NO：2通过取代，缺失或添加1个或几个氨基酸并具有凋亡活性。

    Apoptosis-inducing agent for prostate cancer cells
    14.
    发明授权
    Apoptosis-inducing agent for prostate cancer cells 有权
    前列腺癌细胞凋亡诱导剂

    公开(公告)号：US08658611B2

    公开(公告)日：2014-02-25

    申请号：US13006198

    申请日：2011-01-13

    申请人： Hiromi Kumon ,  Nam-ho Huh ,  Masakiyo Sakaguchi ,  Yasutomo Nasu

    发明人： Hiromi Kumon ,  Nam-ho Huh ,  Masakiyo Sakaguchi ,  Yasutomo Nasu

    IPC分类号： A61K48/00

    CPC分类号： C07K14/4747 ,  A61K38/00

    摘要： According to the present invention, an apoptosis-inducing agent for prostate cancer comprising REIC/Dkk-3 DNA or an REIC/Dkk-3 protein, and a therapeutic agent for prostate cancer and an agent for inhibiting prostate cancer metastasis that comprise such apoptosis-inducing agent are provided.An apoptosis-inducing agent for prostate cancer, comprising, as an active ingredient, an REIC/Dkk-3 protein (a) or (b) or REIC/Dkk-3 DNA (c) or (d): (a) a protein consisting of the amino acid sequence represented by SEQ ID NO: 2; (b) a protein consisting of an amino acid sequence derived from the amino acid sequence represented by SEQ ID NO: 2 by substitution or deletion of 1 or more amino acids; (c) DNA consisting of the nucleotide sequence represented by SEQ ID NO: 1; or (d) DNA that hybridizes under stringent conditions to DNA consisting of a nucleotide sequence complementary to the nucleotide sequence represented by SEQ ID NO: 1 and encodes a protein having apoptosis activity; and a therapeutic agent for prostate cancer comprising such apoptosis-inducing agent are provided.

    摘要翻译： 根据本发明，包含REIC / Dkk-3 DNA或REIC / Dkk-3蛋白的前列腺癌细胞凋亡诱导剂，前列腺癌治疗剂和抑制前列腺癌转移的药剂， 提供诱导剂。 一种用于前列腺癌的凋亡诱导剂，其包含REIC / Dkk-3蛋白（a）或（b）或REIC / Dkk-3 DNA（c）或（d）作为活性成分：（a）蛋白质 由SEQ ID NO：2表示的氨基酸序列组成; （b）通过取代或缺失1个或多个氨基酸由SEQ ID NO：2所示的氨基酸序列衍生的氨基酸序列组成的蛋白质; （c）由SEQ ID NO：1表示的核苷酸序列组成的DNA; 或（d）在严格条件下与由与SEQ ID NO：1所示的核苷酸序列互补的核苷酸序列组成的DNA杂交的DNA，并编码具有凋亡活性的蛋白质; 并提供包含这种凋亡诱导剂的前列腺癌治疗剂。

    ANTIBODY AGAINST CALCIFIED GLOBULE AND USE OF THE SAME
    16.
    发明申请
    ANTIBODY AGAINST CALCIFIED GLOBULE AND USE OF THE SAME 有权
    反对计算全球的抗体及其使用

    公开(公告)号：US20110182817A1

    公开(公告)日：2011-07-28

    申请号：US13000325

    申请日：2009-03-09

    申请人： Eiji Matsuura ,  Hiromi Kumon ,  Kazuo Kojima

    发明人： Eiji Matsuura ,  Hiromi Kumon ,  Kazuo Kojima

    IPC分类号： A61K49/00 ,  C07K16/18 ,  A61K39/395 ,  A61P9/10

    CPC分类号： C07K16/18 ,  A61K2039/505 ,  C07K2317/56 ,  C07K2317/565 ,  G01N33/5088 ,  G01N2800/323

    摘要： The present inventors carried out immunization using renal/urinary calculus-derived calcified globules or carotid artery-derived arteriosclerotic plaques, and then obtained antibodies specific to calcified globules (NLO) via screening with NLO. The present inventors demonstrated that the antibodies reacted specifically to arteriosclerotic lesions (calcified lesions) and visualized arteriosclerotic plaques (in particular, calcified lesions) by using fluorescently labeled antibodies. Accordingly, the present inventors completed the present invention.

    摘要翻译： 本发明人使用肾/尿结石来源的钙化球或颈动脉来源的动脉硬化斑块进行免疫，然后通过NLO筛选获得对钙化球（NLO）特异的抗体。 本发明人证实，通过使用荧光标记的抗体，抗体特异性地反应于动脉硬化损伤（钙化损伤）和可视化的动脉硬化斑块（特别是钙化的损伤）。 因此，本发明人完成了本发明。

    Antibody against calcified globule and use of the same
    18.
    发明授权
    Antibody against calcified globule and use of the same 有权
    抗钙化小球的抗体及其用途

    公开(公告)号：US08410251B2

    公开(公告)日：2013-04-02

    申请号：US13000325

    申请日：2009-03-09

    申请人： Eiji Matsuura ,  Hiromi Kumon ,  Kazuo Kojima

    发明人： Eiji Matsuura ,  Hiromi Kumon ,  Kazuo Kojima

    IPC分类号： C07K16/00 ,  C12P21/08 ,  A61K49/00

    CPC分类号： C07K16/18 ,  A61K2039/505 ,  C07K2317/56 ,  C07K2317/565 ,  G01N33/5088 ,  G01N2800/323

    摘要： The present inventors carried out immunization using renal/urinary calculus-derived calcified globules or carotid artery-derived arteriosclerotic plaques, and then obtained antibodies specific to calcified globules (NLO) via screening with NLO. The present inventors demonstrated that the antibodies reacted specifically to arteriosclerotic lesions (calcified lesions) and visualized arteriosclerotic plaques (in particular, calcified lesions) by using fluorescently labeled antibodies. Accordingly, the present inventors completed the present invention.

    摘要翻译： 本发明人使用肾/尿结石来源的钙化球或颈动脉来源的动脉硬化斑块进行免疫，然后通过NLO筛选获得对钙化球（NLO）特异的抗体。 本发明人证实，通过使用荧光标记的抗体，抗体特异性地反应于动脉硬化损伤（钙化损伤）和可视化的动脉硬化斑块（特别是钙化的损伤）。 因此，本发明人完成了本发明。

    Therapeutic Agent for Malignant Mesothelioma and Immunostimulant
    19.
    发明申请
    Therapeutic Agent for Malignant Mesothelioma and Immunostimulant 有权
    恶性间皮瘤和免疫刺激剂的治疗剂

    公开(公告)号：US20110189237A1

    公开(公告)日：2011-08-04

    申请号：US13056443

    申请日：2009-07-30

    申请人： Hiromi Kumon ,  Yasutomo Nasu ,  Yuji Kashiwakura ,  Masami Watanabe ,  Nam-ho Huh ,  Masakiyo Sakaguchi

    发明人： Hiromi Kumon ,  Yasutomo Nasu ,  Yuji Kashiwakura ,  Masami Watanabe ,  Nam-ho Huh ,  Masakiyo Sakaguchi

    IPC分类号： A61K31/7088 ,  A61P35/00 ,  A61P37/04

    CPC分类号： C07K14/47 ,  A61K35/13 ,  A61K38/00 ,  C12N2799/022

    摘要： According to the present invention, a method for treating malignant mesothelioma using REIC/Dkk-3 and a therapeutic agent for malignant mesothelioma comprising REIC/Dkk-3 are provided. A mesothelioma therapeutic agent is provided, comprising the following REIC/Dkk-3 DNA or a vector comprising the DNA as an active ingredient: (a) a DNA consisting of the nucleotide sequence shown in SEQ ID NO: 1; or (b) a DNA hybridizing under stringent conditions to a DNA consisting of a nucleotide sequence complementary to the nucleotide sequence shown in SEQ ID NO: 1 and encoding a protein having apoptosis-inducing activity and IL-7 production-accelerating activity in cells.

    摘要翻译： 根据本发明，提供了使用REIC / Dkk-3治疗恶性间皮瘤的方法和包含REIC / Dkk-3的恶性间皮瘤治疗剂。 提供间皮瘤治疗剂，其包含以下REIC / Dkk-3 DNA或包含该DNA作为活性成分的载体：（a）由SEQ ID NO：1所示核苷酸序列组成的DNA; 或（b）在严格条件下与由与SEQ ID NO：1所示核苷酸序列互补的核苷酸序列组成的DNA杂交并编码细胞中具有凋亡诱导活性和IL-7生产加速活性的蛋白质的DNA。

    Partial fragment of REIC/Dkk-3 gene and cancer therapeutic agent comprising the same
    20.
    发明申请
    Partial fragment of REIC/Dkk-3 gene and cancer therapeutic agent comprising the same 有权
    REIC / Dkk-3基因的部分片段和包含其的癌症治疗剂

    公开(公告)号：US20100173404A1

    公开(公告)日：2010-07-08

    申请号：US12447044

    申请日：2007-10-24

    申请人： Hiromi Kumon ,  Nam-ho Huh ,  Masakiyo Sakaguchi ,  Yasutomo Nasu ,  Fernando Guillermo Abarzua Cabezas

    发明人： Hiromi Kumon ,  Nam-ho Huh ,  Masakiyo Sakaguchi ,  Yasutomo Nasu ,  Fernando Guillermo Abarzua Cabezas

    IPC分类号： C07K14/435 ,  C07H21/04 ,  C12N15/63

    CPC分类号： C07K16/18 ,  A61K31/711 ,  A61K38/00 ,  A61K48/00 ,  C07K14/4747

    摘要： This invention provides an inducer of apoptosis in cancer cells comprising a fragment of the REIC/Dkk-3 gene and a cancer therapeutic agent comprising the same. This invention also provides a polynucleotide fragment encoding the REIC/Dkk-3 protein (a) or (b), which encodes a polypeptide having apoptosis activity: (a) a polynucleotide encoding a polypeptide comprising an amino acid sequence of amino acid 1 to any of amino acids 39 to 78 of the amino acid sequence of the REIC/Dkk-3 protein as shown in SEQ ID NO: 2; or (b) a polynucleotide encoding a polypeptide comprising an amino acid sequence derived from the amino acid sequence of amino acid 1 to any of amino acids 39 to 78 of the amino acid sequence of the REIC/Dkk-3 protein as shown in SEQ ID NO: 2 by substitution, deletion, or addition of 1 or several amino acids and having apoptosis activity.

    摘要翻译： 本发明提供了包含REIC / Dkk-3基因的片段的癌细胞中的凋亡诱导剂和包含其的癌症治疗剂。 本发明还提供编码具有凋亡活性的多肽的编码REIC / Dkk-3蛋白（a）或（b）的多核苷酸片段：（a）编码包含氨基酸1的氨基酸序列的多肽的多核苷酸至任何 的如SEQ ID NO：2所示的REIC / Dkk-3蛋白的氨基酸序列的氨基酸39至78; 或（b）编码多肽的多核苷酸，其包含衍生自SEQ ID NO：1所示的REIC / Dkk-3蛋白的氨基酸序列的氨基酸1至氨基酸39至78的氨基酸序列的氨基酸序列的氨基酸序列 NO：2通过取代，缺失或添加1个或几个氨基酸并具有凋亡活性。